Hypoxanthine
|
Basic information |
| Metabolite name | Hypoxanthine |
 | HMDB0000157 |
 |
C00262 |
 |
790 |
| Synonyms | NA |
| No. of studies | 53 |
|
Basic information |
| Metabolite name | Hypoxanthine |
| HMDB0000157 |
|
C00262 |
|
790 |
| Synonyms | NA |
| No. of studies | 53 |
|
Relationship between Hypoxanthine and depression (count: 53) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M011 | Type4 | placebo-treated responder group vs. non-responder group | Serum | Human | Unknown |
| Study M013 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Up |
| Study M034 | Type1 | MDD group vs. control group | Urine | Human | Down |
| Study M037 | Type2 | placebo treatment group one-week vs. baseline | Serum | Human | Down |
| Study M048 | Type1 | CVS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M048 | Type2 | CVS + CSGS group vs. CVS group | Hippocampus | Wistar rat | Up |
| Study M048 | Type2 | CVS + fluoxetine group vs. CVS group | Hippocampus | Wistar rat | Up |
| Study M068 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M070 | Type1 | depressed group vs. non-depressed group | Urine | Human | Down |
| Study M076 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M076 | Type2 | CUMS + Lilium saponins group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M076 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M076 | Type2 | CUMS + Anemarrhena saponins group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M081 | Type1 | CUMS group vs. control group | Liver | Wistar rat | Up |
| Study M096 | Type1 | CUMS group vs. control group | Plasma | Wistar rat | Down |
| Study M097 | Type1 | depressed women group vs. control women group | Urine | Human | Down |
| Study M097 | Type1 | depressed men group vs. control men group | Urine | Human | Down |
| Study M1039 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M1072 | Type1 | CUMS group vs. control group | Faece | Cynomolgus monkey | Down |
| Study M1090 | Type1 | CUMS group vs. control group | Plasma | BALb/c mouse | Down |
| Study M1093 | Type1 | CSDS group vs. control group | Serum | C57BL/6N mouse | Up |
| Study M1096 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M1096 | Type2 | CUMS + middle dose of Xiaoyao Pills group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M1096 | Type2 | CUMS + fluoxetine group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M1096 | Type2 | CUMS + high dose of Xiaoyao Pills group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M1097 | Type1 | placebo-treated depression group vs. control group | Faece | Human | Down |
| Study M1098 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1098 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1098 | Type2 | CUMS + L-theanine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1102 | Type1 | nitenpyram group vs. control group, male offspring | Faece | ICR mouse | Down |
| Study M115 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M117 | Type1 | CVS group vs. control group | Faece | Wistar rat | Up |
| Study M130 | Type2 | CSDS + DG group vs. CSDS group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M130 | Type2 | CSDS + venlafaxine group vs. CSDS group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M131 | Type1 | LH group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M204 | Type1 | LPS group vs. control group | Hypothalamus | CD-1 mouse | Down |
| Study M208 | Type1 | GCI model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M454 | Type1 | vascular depression model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M454 | Type2 | vascular depression model + YXST group vs. vascular depression model group | Hippocampus | ICR mouse | Up |
| Study M460 | Type1 | depressed group vs. control group | Liver | Kunming mouse | Up |
| Study M464 | Type1 | drug-naive MDD group vs. control group | Plasma | Human | Down |
| Study M464 | Type1 | drug-treatment MDD group vs. control group | Plasma | Human | Down |
| Study M531 | Type2 | MDD with escitalopram/citalopram treatment, 8-week vs. baseline | Plasma | Human | Down |
| Study M532 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M555 | Type1 | FMT group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M571 | Type1 | LPS group vs. control group | Hypothalamus | CD-1 mouse | Down |
| Study M578 | Type1 | restraint stress offspring group vs. control offspring group | Hippocampus | Sprague-Dawley rat | Up |
| Study M613 | Type1 | CSDS susceptible group vs. control group | Serum | C57BL/6 J mouse | Down |
| Study M677 | Type1 | CVS group vs. control group | Faece | Wistar rat | Up |
| Study M738 | Type2 | CMS + Xiaoyaosan group vs. CMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M740 | Type1 | CUMS group vs. control group | Soleus muscle | Sprague-Dawley rat | Up |
| Study M769 | Type1 | CSDS group vs. control group | Amygdala | Sprague-Dawley rat | Down |
| Study M772 | Type1 | CUMS group vs. control group | Amygdala | Sprague-Dawley rat | Down |
| Study M773 | Type1 | antenatal depression group vs. non-antenatal depression group | Serum | Human | Down |
| Study M787 | Type1 | CRS group vs. control group | Colon | Wistar rat | Up |
| Study M814 | Type1 | CSDS group vs. control group | Serum | C57BL/6J mouse | Down |
| Study M826 | Type1 | CVS group vs. control group | Ileum | Wistar rat | Up |
| Study M826 | Type1 | CVS group vs. control group | Jejunum | Wistar rat | Up |
| Study M826 | Type1 | CVS group vs. control group | Colorectum | Wistar rat | Up |
| Study M826 | Type1 | CVS group vs. control group | Gut | Wistar rat | Up |
| Study M826 | Type2 | CVS + antibiotic group vs. CVS group | Gut | Wistar rat | Down |
| Study M828 | Type2 | ultrasonic radiation + intranasally clomipramine group vs. ultrasonic radiation group | Frontal cortex | Wistar rat | Up |
| Study M828 | Type2 | ultrasonic radiation + intraperitoneally clomipramine group vs. ultrasonic radiation group | Hippocampus | Wistar rat | Down |
| Study M828 | Type2 | ultrasonic radiation + intraperitoneally clomipramine group vs. ultrasonic radiation group | Frontal cortex | Wistar rat | Up |
| Study M844 | Type1 | CORT group vs. control group | PC12 cell | Rat | Up |
| Study M850 | Type1 | reserpine group vs. control group | Brain | C57BL/6 mouse | Down |
| Study M869 | Type1 | CUMS group vs. control group | Peripheral blood mononuclear cell | Sprague-Dawley rat | Down |
| Study M869 | Type2 | CUMS + high dose of Chaigui granules group vs. CUMS group | Peripheral blood mononuclear cell | Sprague-Dawley rat | Up |
| Study M869 | Type2 | CUMS + middle dose of Chaigui granules group vs. CUMS group | Peripheral blood mononuclear cell | Sprague-Dawley rat | Up |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Plasma | Human | Up |
| Study M913 | Type2 | responder group, post-escitalopram treatment vs. baseline | Plasma | Human | Down |
| Study M940 | Type1 | CUMS group vs. control group | Cerebral cortex | Sprague-Dawley rat | Down |
| Study M953 | Type2 | CRS + Shugan Granule group vs. CRS group | Faece | Sprague-Dawley rat | Up |
| Study M956 | Type2 | CUMS + deoiled sunflower seeds group vs. CUMS group | Faece | C57BL/6J mouse | Down |
| Study M956 | Type2 | CUMS + whey protein-based group vs. CUMS group | Faece | C57BL/6J mouse | Down |
| Study M957 | Type1 | CSDS group vs. control group | Hippocampus | C57BL/6 J mouse | Up |
| Study M957 | Type1 | CSDS group vs. control group | Serum | C57BL/6 J mouse | Up |